BIND Therapeutics, a biopharma company developing a new class of highly selective targeted and programmable therapeutics called Accurins, has entered into a global collaboration agreement with Pfizer to develop and commercialize Accurins utilizing select small molecule targeted therapies. The collaboration will use BIND’s Medicinal Nanoengineering platform to impart tissue and cellular targeting capabilities to molecularly targeted drugs.   Pfizer will have the exclusive option to pursue develop...